Cryosite (ASX: CTE) — Perfil da empresa, notícias e dados financeiros
Cryosite is a specialist provider of biological material management, clinical trial logistics, and cord blood and tissue banking services based in Australia.
Cryosite
Cryosite is a specialist provider of biological material management, clinical trial logistics, and cord blood and tissue banking services based in Australia. The company offers specialized cold-chain logistics, temperature-sensitive storage, and distribution services for commercial companies, clinical research organizations, and academic institutions participating in medical trials. Additionally, Cryosite operates licensed cord blood and umbilical cord tissue storage facilities, maintaining preserved stem cell samples for family healthcare use. Its infrastructure includes cryopreservation, biorepository management, and specialized bio-storage facilities equipped to handle temperature ranges from ambient down to liquid nitrogen vapor phase across cryogenic biological inventory management.
Resumo
Operações
Produtos e/ou serviços de Cryosite
- Clinical Trial Logistics: Temperature-controlled distribution, depot services, and regulatory compliant transport management for investigational medicinal products, medical devices, and biological samples supporting pharmaceutical and clinical research organizations across domestic and international research sites.
- Biological Material Storage: Cryogenic and ultra-low temperature bio-repository services providing managed storage solutions for bio-banks, pharmaceutical assets, cellular therapies, and tissue samples utilizing liquid nitrogen, deep-freeze, and ambient controlled environment infrastructure.
- Cord Blood Banking: Collection, processing, cryopreservation, and long-term storage of umbilical cord blood stem cells for newborn families, providing potential future regenerative medicine and cellular therapy applications under strict regulatory compliance.
- Cord Tissue Banking: Specialized processing and cryopreservation of umbilical cord tissue, securing mesenchymal stem cells for potential therapeutic applications in regenerative medicine and clinical treatments through accredited bio-containment storage infrastructure.
- Cell Therapy Logistics: Specialized cold-chain storage and supply chain management for cellular therapies, gene therapies, and advanced therapy medicinal products requiring continuous cryogenic monitoring and rapid point-of-care delivery schedules.
- Bio-Repository Management: Comprehensive biological sample archiving, inventory cataloging, destruction management, and audit-ready data tracking services tailored for biotechnology companies, research institutes, and healthcare organizations operating long-term biological studies.
equipe executiva do Cryosite
- Jane HaoChief Financial Officer
- Andrew KerrExecutive Director
- Alicia SteelGeneral Manager
- Jon StearnsOperations Manager
- Hamish GeorgeCompany Secretary
Histórico de dividendos
Dividendos por ação pagos pela Cryosite, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2025 | A$0.0200 | — | — | A$0.0200 |
| FY2024 | A$0.0150 | — | — | A$0.0650 |
| FY2023 | A$0.0100 | — | — | A$0.0100 |
| FY2017 | A$0.0050 | A$0.0050 | — | A$0.0100 |
| FY2016 | A$0.0050 | A$0.0050 | — | A$0.0100 |
Principais indicadores financeiros
Resultados divulgados pela Cryosite, em AUD.
- Cap. de mercado
- 59,5 mi
- Receita (TTM)
- 16,7 mi
- P/L
- 30.5
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- 13.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 16,7 mi | 3,2 mi | 2,2 mi | |
| 14,1 mi | 2,5 mi | 1,9 mi | |
| 12,6 mi | 2,1 mi | 1,8 mi | |
| 11,9 mi | 1,5 mi | 1,4 mi |